Last updated: April 25, 2026
Singapore Drug Patent SG10201808055Q: Scope, Claims, and Patent Landscape
What is SG10201808055Q and what does it protect?
SG10201808055Q is a Singapore patent application/publication directed to a specific drug-related invention. The scope is defined by the independent claims and limited by the claim language, the specification’s described embodiments, and the applicable Singapore claim interpretation standard for patent claims (i.e., a claim construction anchored in the description and the person skilled in the art).
However, a complete, accurate scope-and-claims analysis requires the actual published claim set and bibliographic record for SG10201808055Q. Without the claim text and publication details (title, applicant/assignee, priority, IPC/CPC, publication date, and the full claim set), any attempt to state “what it protects” would be incomplete and risk inaccuracy.
What do the claims likely cover (and how is claim scope determined)?
Claim scope is determined by:
- Independent claim language (core invention definition, product and/or method steps, essential structural or functional limitations).
- Dependent claims (narrowing limitations, embodiments, preferred parameters, specific salts, polymorphs, formulations, dosing regimens, or use claims).
- Terminology in the claims (e.g., “comprising” vs “consisting,” “effective amount,” “pharmaceutically acceptable,” whether features are structural vs functional).
- Support in the specification (how broadly the disclosure supports each claim; prevents overreach during construction).
A reliable mapping from SG10201808055Q to its practical protection requires the actual claim text. The claim-level breakdown (element-by-element, infringement-relevant interpretation, design-around vectors) cannot be produced without the claims.
What is the patent landscape around SG10201808055Q in Singapore?
A proper landscape requires tying SG10201808055Q to:
- Family members (same priority across EP/US/WO, counterpart Singapore filings, and any amendments).
- Competing filings in Singapore (priority-to-publication overlap in similar therapeutic classes).
- Regulatory exclusivities and linkages if applicable (e.g., Singapore patent listing if the patent is relevant to marketing authorization).
- Expiry and term (including any patent term adjustments, if present, and the effect of any earlier filing dates in the family).
A reliable landscape requires the publication record of SG10201808055Q and the corresponding international family. Without those bibliographic identifiers, it is not possible to enumerate the closest blocking or design-around patents in Singapore.
Which related patents matter most (family, closest prior art, and design-arounds)?
For Singapore drug patent analysis, the main “decision-grade” artifacts usually include:
- WO/EP/US family counterparts (for claim construction consistency and to identify the narrowest claim set).
- Prior art patents cited in prosecution (to locate likely invalidity themes).
- Later filings by other parties in the same target (to identify whether SG10201808055Q blocks those new claim pathways).
This analysis cannot be completed without the prosecution/publication data and claim text for SG10201808055Q.
Patent-Claim Extraction Checklist (Required to Complete This Analysis)
To deliver the “scope and claims and patent landscape” you requested in a litigation-ready format, the following must be extracted from the SG10201808055Q record:
- Publication number and publication date
- Applicant/assignee
- Title and abstract
- Priority application numbers and priority dates
- Classification (IPC/CPC)
- Full claim set (independent and dependent claims)
- Whether claims are directed to: compound(s), salt/polymorph, formulation, method of treatment, use, or process
- Any claim amendments across publications/grants
- Cited references (if available)
- Family members and their status in major jurisdictions
Without these data elements, a complete and accurate patent scope and landscape cannot be produced.
Key Takeaways
- A complete, accurate analysis of SG10201808055Q’s claim scope and patent landscape cannot be produced without the published claim text and bibliographic/publication record for SG10201808055Q.
- Claim construction and landscape mapping are claim-driven exercises: without the independent claim elements and dependent limitations, no credible protection boundaries or infringement/design-around analysis can be stated.
FAQs
1) What is the fastest way to understand SG10201808055Q’s protection?
Read and interpret the independent claims first, then test each dependent claim limitation for added constraints. This requires the full claim text.
2) Does SG10201808055Q likely protect a molecule, a formulation, or a method?
That depends entirely on the claim language. Only the claims define the protected subject matter.
3) How do you identify the key blocking patents in Singapore?
By mapping the family and the closest therapeutic/compound/formulation overlaps in Singapore, then comparing claim elements.
4) Can design-arounds be assessed without claim construction?
No. Design-arounds require knowing which features are essential claim limitations and which are optional or broadly described.
5) How is claim scope affected by the specification?
Under standard claim construction practice, claims are read with the specification for context and meaning. Overbroad interpretations are constrained by support and definition in the disclosure.
References
[1] Singapore IP Office (IPOS). Patent publication/records for SG10201808055Q (bibliographic record and full specification).
